DATA GRAPHICS | Product Development
The TREM2 pipeline: Date Byte
It’s early days for the target, but the therapies directed at the innate immune receptor has begun to reflect its potential
September 28, 2021 9:09 PM UTC
Updated on Oct 1, 2021 at 5:15 PM UTC
It’s early days for TREM2 as drug target, but the small pipeline of therapies directed at the innate immune receptor has begun to reflect the target’s potential for different use cases across neuroinflammation and cancer immunity.
Of the five disclosed programs targeting TREM2, three are in development for Alzheimer’s disease, including the most advanced therapy, Phase II antibody AL002 from Alector Inc. (NASDAQ:ALEC) and AbbVie Inc. (NYSE:ABBV)...